Results 121 to 130 of about 644,957 (254)
TWIST1 bridges p53 and MDM2 and impairs the efficacy of MDM2 inhibitors
Journal of Experimental & Clinical Cancer ResearchAbstract Background Tumors that retain wild-type TP53 and rely on MDM2 overexpression to dampen the p53 response were considered prime candidates for therapies based on MDM2 inhibitors (MDM2i).
Sara Piccinin +10 more
openaire +1 more source
Phytotherapy Research, EarlyView.PTA alleviates atherosclerosis by regulating the MDM2/GPX4 axis‐mediated endothelial ferroptosis. ABSTRACT Endothelial ferroptosis is a crucial pathogenic driver of atherosclerosis (AS) progression. Protosappanin A (PTA), a bioactive compound from Caesalpinia sappan L., protects cardiovascular vessels by regulating ferroptosis.
Jiamei Fu +6 more
wiley +1 more source
Stimuli‐responsive nanostructured hydrogen sulfide donors for enhanced cancer treatments
Smart Molecules, EarlyView.Three typical kinds of stimuli‐responsive nanostructured hydrogen sulfide (H2S) donors are reviewed. The nanostructures ensure precise delivery of H2S to the lesion site and regulate the release behavior. The H2S‐based gas therapy has been used to synergize with other cancer treatment modalities, achieving enhanced efficacy while reducing side effects.
Yuxuan Lyu +7 more
wiley +1 more source
Frontiers in ChemistryBackgroundBreast cancer (BC) remains a leading cause of cancer-related mortality in women. The oncoprotein MDM2 negatively regulates the tumor suppressor p53, and its overexpression in BC promotes tumor progression and resistance to therapy.
Eva Azme +12 more
doaj +1 more source
Smart Molecules, EarlyView.AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin +10 more
wiley +1 more source
Carbon monoxide (CO) is an endogenous signaling molecule with known pharmacological activities in a range of animal model studies, including inflammation, cancer, and organ protection.
Tripathi, Ravi
core +1 more source
Andrology, EarlyView.ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick +7 more
wiley +1 more source
A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics
Andrology, EarlyView.ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis +3 more
wiley +1 more source
Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors
, 2016 A successful structure-based design of a class of non-peptide small-molecule MDM2 inhibitors targeting the p53−MDM2 protein−protein interaction is reported.
Su Qiu (340076) +12 more
core +1 more source